
Sign up to save your podcasts
Or


Send us Fan Mail
Ankit Anand doesn't fit the typical venture capital mold. He started his career as a physics teacher in India, moved to Europe to work on gravitational wave research at ETH Zurich, co-founded a medical technology company, and only then — after years of operating and angel investing — ended up as Founding Partner at Riceberg Ventures. Today, Riceberg backs breakthrough deep tech companies across space, cybersecurity, AI, life science, and frontier industries — often writing the first check before a company is even incorporated.
This conversation matters because Ankit brings a rare lens to early-stage investing: the discipline of a trained scientist, the scar tissue of an operator, and a global perspective that spans Europe, India, and the United States. For founders raising capital — or investors thinking about how to back hard technology — he offers an unusually clear framework for how to separate breakthrough companies from noise, and why the VC game is fundamentally a trust business, not a finance one.
Key Topics Covered
Three Key Insights
Links
About Ankit Anand
Ankit is Founding Partner at Riceberg Ventures. He came to venture the long way — teaching physics in India, then doing gravitational wave research at ETH Zurich on the LIGO project, then co-founding a medical technology company in Europe. Riceberg writes first checks into deep tech founders, often before the company is even registered, and invests globally out of offices across Europe, India, and the U.S.
Send us Fan Mail
Debneel Mukherjee is the kind of investor most founders never get access to — a former CPA turned self-taught coder turned operator turned venture capitalist, now running Decacorn.VC from Singapore, with roughly 85% of his portfolio deployed in the United States. His career spans nearly three decades across banking, fintech operations, and global private tech investing, and he's built a track record that includes early bets on companies such as Palantir, Mapbox, ThoughtSpot, BioCatch, and SpaceX — well before most of those names became consensus trades. He currently holds two portfolio companies in the S&P 500.
The reason we wanted Debneel on the show is simple — he doesn't invest the way most VCs do, and he'll tell you exactly why. He won't touch institutional money. He doesn't limit himself to what's within driving distance. And he's not interested in markets that already exist. His whole thesis is built on first principles: find the bottleneck, find the founder crazy enough to solve it, and then get out of their way. Most investors talk about being contrarian. Debneel actually built a fund around it — from Singapore, into the US, with the patience to hold through the storms that shake everyone else out.
Key Topics Covered
Key Insights
Links
Guest Bio
Debneel Mukherjee founded Decaco
Send us Fan Mail
Robin Smith, a 20-year enterprise software veteran, has worked through all ownership models—bootstrapped, venture-backed, private equity, and public. Most recently, as COO of a PE-backed portco with 1,000+ employees, he led over €200 million in acquisitions during an 18-month roll-up. Now in his mid-40s, he left that world to pursue entrepreneurship through acquisition and found that AI is rewriting the playbook for buying mission-critical software businesses.
What makes this conversation worth your time is where Robin is standing right now. He knows how PE deals actually work — from the inside, not from a pitch deck. He watched AI gut the economics of traditional SaaS in real time. And he's acting on it, building Stayd as a B Corp roll-up of holiday home agencies in the UK with a thesis that most of the market is still sleeping on. He doesn't sugarcoat the deal that fell apart, he's blunt about where software valuations are headed, and his thinking on outcome-based pricing is ahead of the curve. This is one of the more honest conversations we've had on the show.
5 Key Topics Covered
3 Key Insights
Links
Guest Bio
Robin Smith is the Managing Partner of Corinium Capital and the Founder of Stayd, a B Corp roll-up of
Send us Fan Mail
Kim Anders Odhner is the Managing Partner for Europe and Asia at Unovis Asset Management, a leading alternative protein investment fund. Before relocating to Amsterdam, Kim spent 25 years in Southeast Asia, developing expertise in emerging-markets private equity — backing early-stage companies, staying involved post-investment, and understanding food systems across diverse economies. He co-founded the New Crop Capital Trust with Chris Kerr and has been investing in food tech since the sector's early days, with investments in Beyond Meat, Oatly, Mosa Meat, and Aleph Farms.
This conversation is important because the food tech investment scene has changed significantly. The 2021–2022 hype has cooled, early-stage funding is scarce, and the idea that "build it and they will come" has been tested — often unsuccessfully. Kim combines frontier-market investing discipline with deep food-system knowledge that cuts through the noise. Whether you're a food tech founder, an investor, or just wondering how we'll feed 10 billion people by 2050, this episode provides clarity.
These are some of the key topics covered:
Some of the insights from our talk were:
Links & Resources:
Learn more about Kim and the organizations mentioned in this episode:
About the Guest
Kim Anders Odhner runs Unovis Asset Management's Europe and Asia practice. He backed companies like Beyond Meat, Oatly, and Mosa Meat before most investors knew alternative protein was a category. Before Amsterdam, he spent 25 years doing private equity deals across Vietnam, Hong Kong, and Singapore — and he's now raising Unovis's third fund to back food tech companies at the growth stage.
Send us Fan Mail
Dr. Henry Erdlei is a physician-scientist pushing the boundaries of cancer immunotherapy. An alumnus of Charité Medical School and a researcher at the Max Delbrück Center for Molecular Medicine in Berlin, Henry has dedicated years to engineering immune cells to hunt and destroy tumors — and he is now applying that expertise to GoCART Therapeutics, a biotech startup developing a modular CAR-T cell platform that could revolutionize cancer treatment. His work sits at the crossroads of biology, engineering, and AI-driven drug design.
This conversation highlights CAR-T therapy, a highly effective cancer treatment not yet available for 70% of cancer types. Targeting antigens on vital tissues like the brain and bone marrow is risky, but GoCART's 'AND gate' system requires two antigens for activation, enabling it to target 'undruggable' cancers. Henry discusses the science, business plan, funding, and his views on drug regulation in straightforward language.
KEY TOPICS COVERED
1. The Undruggable Antigen Problem: Why 70% of cancer types can't be treated with current CAR-T therapy — and how the best tumor markers are also found on tissues you can't afford to destroy.
2. GoCART's AND Gate: Dual-Antigen Recognition. How GoCART's modular system needs two antigens on a cell for activation, allowing precise tumor targeting without collateral damage.
3. AI-Driven Peptide Engineering at Scale: How machine learning enabled GoCART to analyze 180,000 trimeric sequences computationally — a process that would have cost over €200M in laboratory work — and reduce it to 20 validated candidates.
4. The Platform Business Model: Why GoCART is building the "operating system" for CAR-T therapy — a single universal cell product with swappable binders — and how partners can develop and sell binders on the platform.
5. Rethinking Drug Regulation: Henry's argument that the orphan approval pathway should become the standard: provide treatments to patients after Phase II with informed consent, conduct Phase IV surveillance on the market, and significantly reduce costs.
KEY INSIGHTS
1. The real challenge in cancer immunotherapy isn't whether CAR-T cells are effective — it's that most of the best targets for treatment are also found on healthy tissue, meaning the therapy could destroy vital organs along with the tumor. GoCART's dual-recognition system eliminates this limitation.
2. Personalized medicine doesn't have to mean creating a new drug for each patient. By modularizing the system — one universal CAR-T cell, many interchangeable binders — GoCART provides patient-specific treatment on an industrial scale, with the potential to reduce costs from $800K to just a few thousand over time.
3. The current Phase III clinical trial requirement adds hundreds of millions in costs and years of delay before patients can access treatments that are already proven effective after Phase II. Moving to a market-while-monitoring model could deliver effective therapies to patients more quickly, generate more comprehensive real-world data, and lower drug prices overall.
LINKS
GUEST BIO
Dr. Henry Erdlei is the Co-Founder of GoCART Therapeutics, a Berlin-based biotech startup developing a modular CAR-T cell platform to advance precision cancer immunotherapy. He is a physician-scientist trained at the Charité Medical School and the Max Delbrück Center for Molecular Medicine (Helmholtz), where his research focused on engineering immune cells for tumor targeting.
Send us Fan Mail
Oded Agam | NextLeap Ventures — Deep Tech Investing, the Intel AI Miss, and Building Innovation Ecosystems
Oded Agam is one of those rare investors who has actually built what he now funds. With 35 years spanning Israeli startups, Fortune 50 strategic planning at Intel, and early-stage deep tech investing through NextLeap Ventures, Oded brings an operator's lens to every deal. He led Intel's Strategic Technologies Group — the unit responsible for identifying and incubating transformational technologies — and drove strategic planning for product lines generating over $30 billion in revenue. When he left Intel in 2017, he called four former colleagues and started a venture fund.
This conversation matters because Oded doesn't deal in theory. He walks through how NextLeap narrows nearly 1,000 startups down to three investments per cycle, why he pitched a $300 million AI program to Intel leadership in 2014 that could have changed the chip industry's trajectory, and what founders consistently get wrong in a pitch. Whether you're raising capital or refining your investment thesis, this is a masterclass in disciplined deep tech investing from someone who has sat on both sides of the table.
Key Topics Covered
Key Insights
Links
Guest Bio
Oded Agam is the Managing Partner and Founder of NextLeap Ventures, an Israeli-based early-stage deep tech venture fund with 26 portfolio companies and three successful exits — including acquisitions by Synopsys, Nano Dimension, and Dell. Before founding NextLeap in 2017, he spent over 11 years at Intel, leading strategic planning for product lines generating more than 80% of Intel's global revenue and heading the Strategic Technologies Group.
Send us Fan Mail
EP004 — Charles Cormier on Systems, Cold Email, and Why Most Founders Get Fundraising Wrong
Charles Cormier is a founder who doesn’t wait for permission. As CEO of RaasRocket and founder of GTM Ventures and the Podbuyer podcast network, he’s learned that fundraising today is just as much about the systems you build as the people you know. In this episode, he sits down with Maxim Atanassov to unpack why traditional approaches like warm intros and VC lunches often fall flat—and what to do instead. His take is simple, practical, and grounded in real outcomes, all shaped by a first-principles, energy-efficient way of working.
We dig into how capital markets have shifted: hype alone is no longer enough to get you funded, and a lot of founders haven’t caught up. Charles has worked with hundreds of founders on fundraising and go-to-market strategy and keeps seeing the same patterns show up again and again.
Here are a few of the most interesting things we cover:
3 Key Insights
These are some of the key insights from our talk:
About Charles Cormier
Charles Cormier is a serial entrepreneur, CEO of RaasRocket, and founder of GTM Ventures and the Podbuyer podcast network. He helps founders raise capital and speed up their go-to-market efforts through systems-driven cold outreach, strategic podcasting, and first-principles thinking.
Send us Fan Mail
From Combat Tours to Term Sheets: Paul Claxton on Founders, Capital, and AIGuest: Paul Anthony Claxton, Managing Partner, Digerati Investments
About This Episode
Paul Anthony Claxton didn't follow the usual route into venture capital. He served four combat tours in Iraq as a United States Marine — including leading a command intelligence center where he observed the early days of drone warfare — before enduring six years of corporate layoffs, building a bootstrapped company to $20K MRR in three months, and eventually moving into early-stage investing. Today, he manages Digerati Investments, a $60 million AI-focused seed and Series A fund based in Southern California.
This conversation is worth your time because Paul operates at a rare intersection: operator empathy, military-grade discipline, and a genuine sophistication around capital strategy that most early-stage investors don't bring to the table. He's not interested in hype. He's interested in founders who understand what they're building, why they're raising, and whether venture capital is even the right tool for their business — a conversation most of the industry is still too afraid to have.
Key Topics Covered
Key Insights:
1. Mental toughness is the true competitive advantage. The Marine Corps taught Paul that the toughest challenges are conquered brick by brick — with speed, intensity, and relentless focus on the smallest details. That same approach guides how he evaluates founders today.
2. Venture capital is not the default answer. Many founders assume that starting a company requires raising VC. Paul argues that understanding the complete capital stack — debt, ARR financing, venture debt, angel investment — and knowing why you're choosing VC is one of the most crucial hard skills a founder can develop.
3. AI is in its foundation-building phase — and most of what's out there won't survive it. Paul's view: the companies being built between now and roughly 2030 will serve as the foundational layer of the AI era — the next Googles and PayPals. Everything else driven by hype, lacking genuine utility or real-world impact, will fade away.
Links & Resources
Guest B
Send us Fan Mail
Ray Fitzpatrick, Founder & CEO, Profitual
Ray Fitzpatrick spent ten years writing checks to startups as Director of Investments at NBIF — New Brunswick's pre-seed venture capital fund — and observed the same issue recurring across hundreds of companies. Founders excelled at developing products but struggled to grasp their own finances. This wasn’t due to laziness, but because no accessible tool existed for non-finance professionals to use effectively. That's the challenge Profitual aims to address.
This discussion extends far beyond the product itself. Ray is a CPA and a serial entrepreneur managing three businesses at once, with firsthand experience on both sides of the investor table. His insights into fundraising, co-founder relationships, cap table design, and what financial literacy truly means for a scaling founder are rooted in real-world experience — not just theory. If you're building a company and have ever felt nervous when your investor asked about burn rate or runway, this is for you.
Key Topics Covered
3 Key Insights
Links & Resources
About Ray Fitzpatrick
Ray Fitzpatrick is the Founder and CEO of Profitual, a financial forecasting and reporting platform for startup founders and SME operators without a finance background. A CPA, Ray spent a decade as Director of Investments at NBIF, participating in over 200 financings and helping build a portfolio of 75 startups in New Brunswick. He's also a co-founder of Quantified Accounting and Devil's Keep Distillery, dedicating his time to developing Profitual and mentoring future founders.
Send us Fan Mail
From EdTech Exit to AI Agents: Scaling on Your Own Terms with David Kofoed Wind
Guest: David Kofoed Wind ·(Founder of Agentwork)
David Kofoed Wind has accomplished what most founders only talk about — building two companies from scratch, taking them through Y Combinator, scaling them responsibly without overextending on headcount, and selling one of them. He's a mathematician with a PhD in machine learning, a former CERN collaborator, and someone who has been seriously considering AI since he was thirteen. Now he's back in the game with Agentwork, a company rethinking how work gets done when AI and humans work together side by side.
This conversation is valuable for founders trying to understand where AI genuinely fits into their operations — not just the hype, but the real substance. David speaks plainly about what has changed, what stays the same, and why pursuing headcount growth was never a smart move. He has been working at the forefront of this shift longer than most, and his insights on distribution, moats, and the future of digital work are based on hard-earned experience rather than speculation.
Topics covered
Key insights from the Episode
About David Kofoed Wind
David Kofoed Wind is the founder of Agentwork, a human-in-the-loop AI platform designed for business teams that need complex work done reliably and at scale. He previously co-founded Peergrade and Eduflow, both Y Combinator companies that grew through product-led growth and were ultimately acquired by Mountiverse. David holds a PhD in machine learning and brings a rare combination of deep technical fluency and operator experience to every problem he addresses.
From the publisher's feed
Future Ventures: Clarity at Scale is the podcast for founders, operators, and investors who are building companies worth owning for the long term — and who need to think clearly about…
Each episode cuts through the noise around scaling: how to structure a deal, how to position a business for institutional capital, how to build operational leverage without losing control, and how to make the high-stakes decisions that compound in value long after the moment has passed.
Hosted by Maxim Atanassov — a four-time founder and the Managing Partner of Future Ventures Corp. Since 2018, FVC has invested in, incubated, and scaled companies across sectors — with a focus on platform opportunities that compound in value. Maxim's background spans executive leadership inside Canada's largest energy companies and senior advisory at Deloitte and EY. He's a CPA-CA who has sat at the table where capital gets deployed, governance gets built, and hard decisions get made. Now he helps founders get there faster.
New episodes every week. Subscribe wherever you listen.